NAS:CPIX (USA) Also trade in: Germany

Cumberland Pharmaceuticals Inc

$ 6.3 0 (0%)
Volume: 51,000 Avg Vol (1m): 19,927
Market Cap $: 97.89 Mil Enterprise Value $: 83.37 Mil
P/E (TTM): 0.00 P/B: 1.75
Earnings Power Value 2.3
Net Current Asset Value -0.08
Tangible Book 1.4
Projected FCF 2.09
Median P/S Value 7.36
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.71
Cash-To-Debt ranked higher than
59.37% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
CPIX: 1.71
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.16, Med: 9.29, Max: 10000
Current: 1.71
1.16
10000
Equity-to-Asset 0.48
Equity-to-Asset ranked higher than
55.71% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
CPIX: 0.48
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.42, Med: 0.8, Max: 0.91
Current: 0.48
0.42
0.91
Debt-to-Equity 0.36
Debt-to-Equity ranked higher than
62.08% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
CPIX: 0.36
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.02, Med: 0.11, Max: 0.49
Current: 0.36
0.02
0.49
Debt-to-EBITDA -17.36
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
CPIX: -17.36
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -17.36, Med: 0.46, Max: 3.51
Current: -17.36
-17.36
3.51
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.61
DISTRESS
GREY
SAFE
Beneish M-Score -2.03
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -17.34%
WACC 1.49%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -11.61
Operating Margin ranked lower than
75.28% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
CPIX: -11.61
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -18.14, Med: 6.48, Max: 19.26
Current: -11.61
-18.14
19.26
Net Margin % -10.57
Net Margin ranked lower than
76.68% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
CPIX: -10.57
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -19.39, Med: 3.77, Max: 11.96
Current: -10.57
-19.39
11.96
ROE % -8.02
ROE ranked lower than
72.96% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
CPIX: -8.02
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -11.62, Med: 1.98, Max: 7.04
Current: -8.02
-11.62
7.04
ROA % -4.69
ROA ranked lower than
71.53% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
CPIX: -4.69
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -8.55, Med: 1.65, Max: 6.03
Current: -4.69
-8.55
6.03
ROC (Joel Greenblatt) % -648.02
ROC (Joel Greenblatt) ranked lower than
88.65% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
CPIX: -648.02
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -648.02, Med: 74.85, Max: 182.86
Current: -648.02
-648.02
182.86
3-Year Total Revenue Growth Rate 6.70
3-Year Revenue Growth Rate ranked higher than
57.62% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
CPIX: 10
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -7.4, Med: 5.4, Max: 47.3
Current: 10
-7.4
47.3

» CPIX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CPIX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare OSTO:PLED XKRX:003120 NAS:DRRX NAS:SXTC XKRX:086080 OTCPK:VFRM XCNQ:SPR TSE:4539 TSX:CORV ROCO:6553 XPAE:BPC JSE:ADE NZSE:CVT ROCO:6535 TSE:4594 XCNQ:DIXI.U DHA:ORIONPHARM OTCPK:EDXC ISX:PEHA ASX:AGH
Traded in other countries CBJ.Germany
Address 2525 West End Avenue, Suite 950, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It focuses on the acquisition, development, and commercialization of branded prescription products. The company provides prescription products to hospital acute care and gastroenterology to address unmet or poorly met medical needs. Its product brands include Acetadote, Caldolor, Kristalose, Omeclamox- Pak, Vaprisol and Ethyol.

Ratios

Current vs industry vs history
PB Ratio 1.75
PB Ratio ranked higher than
75.21% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
CPIX: 1.75
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.9, Med: 1.42, Max: 4.83
Current: 1.75
0.9
4.83
PS Ratio 2.23
PS Ratio ranked higher than
59.10% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
CPIX: 2.23
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.65, Med: 2.6, Max: 6.81
Current: 2.23
1.65
6.81
Price-to-Operating-Cash-Flow 39.13
Price-to-Operating-Cash-Flow ranked lower than
100.00% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
CPIX: 39.13
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 11.3, Med: 31.24, Max: 7100
Current: 39.13
11.3
7100
EV-to-EBIT -18.45
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
CPIX: -18.45
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -377.8, Med: 5.9, Max: 993.7
Current: -18.45
-377.8
993.7
EV-to-EBITDA -72.37
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
CPIX: -72.37
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -174.2, Med: 6.7, Max: 62.6
Current: -72.37
-174.2
62.6
EV-to-Revenue 1.90
EV-to-Revenue ranked higher than
81.26% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
CPIX: 1.9
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.2, Med: 1.3, Max: 6.2
Current: 1.9
0.2
6.2
Current Ratio 2.07
Current Ratio ranked higher than
71.58% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
CPIX: 2.07
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.45, Med: 5.62, Max: 14.46
Current: 2.07
1.45
14.46
Quick Ratio 1.67
Quick Ratio ranked higher than
72.40% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
CPIX: 1.67
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.38, Med: 5.1, Max: 13.46
Current: 1.67
1.38
13.46
Days Inventory 407.09
Days Inventory ranked lower than
90.86% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
CPIX: 407.09
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 290.54, Med: 404.81, Max: 636.33
Current: 407.09
290.54
636.33
Days Sales Outstanding 82.63
Days Sales Outstanding ranked higher than
71.82% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
CPIX: 82.63
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 40.93, Med: 53.12, Max: 82.63
Current: 82.63
40.93
82.63
Days Payable 432.10
Days Payable ranked higher than
95.38% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
CPIX: 432.1
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 103.04, Med: 225.25, Max: 548.79
Current: 432.1
103.04
548.79

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 1.60
3-Year Share Buyback Rate ranked higher than
97.37% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
CPIX: 1.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -7, Med: 2.1, Max: 5.1
Current: 1.6
-7
5.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.50
Price-to-Tangible-Book ranked higher than
65.15% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
CPIX: 4.5
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.04, Med: 1.73, Max: 5.21
Current: 4.5
1.04
5.21
Price-to-Projected-FCF 3.01
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
52.67% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
CPIX: 3.01
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.7, Med: 1.17, Max: 3.1
Current: 3.01
0.7
3.1
Price-to-Median-PS-Value 0.86
Price-to-Median-PS-Value ranked higher than
56.12% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
CPIX: 0.86
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.65, Med: 1.03, Max: 2.5
Current: 0.86
0.65
2.5
Earnings Yield (Joel Greenblatt) % -5.42
Earnings Yield (Greenblatt) ranked lower than
84.20% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
CPIX: -5.42
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -18.2, Med: 3.4, Max: 79.2
Current: -5.42
-18.2
79.2
Forward Rate of Return (Yacktman) % -0.45
Forward Rate of Return ranked lower than
70.31% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
CPIX: -0.45
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -0.45, Med: 3.9, Max: 18.9
Current: -0.45
-0.45
18.9

More Statistics

Revenue (TTM) (Mil) $ 44.06
EPS (TTM) $ -0.31
Beta -0.1
Volatility % 30.8
52-Week Range $ 4.83 - 7
Shares Outstanding (Mil) 15.54

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y